Single User
£4350
PDF
74 pages

MPS-III (Sanfilippo Syndrome) Forecast in 23 Major Markets 2017-2027


Mucopolysaccharidosis-III, also known as MPS-III or Sanfilippo syndrome, is part of the Mucopolysaccharidoses (MPS) disorders - a group of rare genetic disorders caused by deficiencies of lysosomal enzymes. These are in-born errors of metabolism, and are autosomal recessive genetic disorders.

There are 4 distinct sub-types of MPS-III (A, B, C & D), with patients ranging from mild to severe in terms of symptoms. Prevalence of the different subtypes varies markedly country to country.

This report provides the current prevalent population for MPS-III across 23 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Australia, Netherlands, Denmark, Sweden, Norway, Turkey, Greece, Portugal, Poland, Estonia, Russia, Czech Republic) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of MPS-III have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for MPS-III disease include:

  • Hernia
  • Hearing loss and otitis
  • Sleep disorders
  • Neurological and behavioural disorders

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global MPS-III market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of MPS-III and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on MPS-III prevalent population.
  • Identify sub-populations within MPS-III which require treatment.
  • Gain an understanding of the specific markets that have the largest number of MPS-III patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line prevalence for MPS-III
    • Main Subtype
  • Features of MPS-III patients
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • Prevalence of MPS-III, total (000s)
  • Prevalence of MPS-III, males (000s)
  • Prevalence of MPS-III, females (000s)
  • MPS-III patients by Sub-type, total (000s)
  • MPS-III patients with coarse features, total (000s)
  • MPS-III patients with Hepatomegaly, total (000s)
  • MPS-III patients with language delay, total (000s)
  • MPS-III patients with Abnormal behaviour, total (000s)
  • MPS-III patients with ASD, total (000s)
  • MPS-III patients with epilepsy, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • USA Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Canada Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Canada Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • France Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • France Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Germany Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Germany Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Italy Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Italy Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Spain Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Spain Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • UK Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • UK Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Brazil Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Brazil Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Japan Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Japan Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • India Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • India Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • China Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • China Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Russia Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Russia Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Australia Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Australia Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Netherlands Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Netherlands Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Denmark Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Denmark Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Sweden Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Sweden Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Norway Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Norway Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Turkey Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Turkey Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Greece Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Greece Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Portugal Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Portugal Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Poland Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Poland Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Estonia Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Estonia Prevalence of MPS-III by 5-yr age cohort, females (000s)
  • Czech Republic Prevalence of MPS-III by 5-yr age cohort, males (000s)
  • Czech Republic Prevalence of MPS-III by 5-yr age cohort, females (000s)
Australia, Brazil, Canada, China, Czech Republic, Denmark, Estonia, France, Germany, Greece, India, Italy, Japan, Netherlands, Norway, Poland, Portugal, Russian Federation, Spain, Sweden, Turkey, United Kingdom, United States of America